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The Virus
WHAt Is It
• Discovered in 1975 in asymptomatic blood donors.
• small Dna virus ('parvum' being Latin for small).
• B19V only infects humans.
• Causative agent of erythema infectiosum (fifth disease of childhood).
WHAt Is tHE sErOprEvAlEnCE OF B19v
• approximately 60%. 1, 5 HOW Is It sprEAD
• Transmission is greatest during viremia and before symptoms arise.
• The virus is spread via aerosol droplets through the respiratory route.
• Transmitted by hand-to-mouth contact, blood or blood products and nosocomial infection.
• Can be spread transplacentally to the fetus during active maternal infection (33% transmission rate across the placenta).
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• During outbreaks, infection rates of 25 and 50% have been noted in the school and home, respectively. The Virus
WHEn DO InFECtIOns/OutBrEAks OCCur?
• Parvovirus B19 infection can occur at any time.
• The majority of outbreaks tend to be in the Winter and spring time.
WHAt CEll typEs ArE InFECtED?
• Preferentially infects and replicates in erythroid cells.
• Following B19V infection, erythrocytes will lyse arresting erythropoiesis.
• Lymphocyte, granulocyte and platelet counts may also fall during infection.
• The B19V incubation period is usually 4-14 days.
WHO Is At rIsk OF InFECtIOn?
• all non-immune individuals (up to 50% of the population).
• a higher risk of infection exists in school and child care personnel. • Pregnant women and their fetuses.
• highest risk of infection for pregnant women is during epidemics and following exposure to infected children in the home. 4 • Persons with pre-existing anemia and congenital or acquired immunodeficiencies.
WHAt Is tHE InCIDEnCE OF InFECtIOn
In prEgnAnt WOmEn?
• It has been estimated that maternal B19V infection occurs in approximately 1 in every 400 pregnancies.
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CAn B19v InFECtIOn BE trEAtED?
• high titre immunoglobulin treatment has been shown to be effective against the virus.
• The clinical manifestations of B19V infection can also be treated through intrauterine transfusion.
• Work is being carried out at present to produce a vaccine for B19V. 
Clinical Manifestations
WHAt ArE tHE COnsEquEnCEs OF B19v InFECtIOn FOr tHE FEtus?
• FETaL anEMIa:
> B19V preferentially infects and replicates in erythroid cells.
> active B19V infection causes fetal anemia.
> anemia is an underlying factor in the development of hydrops, ascites and can lead to fetal loss.
• non-IMMunE hyDRoPs FETaLIs (nIhF):
> B19V infection induces severe anemia which leads to nIhF.
> The most common form of hydrops is nIhF (~75% of cases).
> 10-20% of cases of idiopathic nIhF are B19V-associated. 7, 8 > hydrops usually occurs 2-4 weeks after maternal B19V infection.
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> on average, there is a 10% risk of hydrops following B19V infection.
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• FETaL Loss:
> up to 10% of B19V infections during pregnancy are associated with fetal loss.
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> The majority of fetal losses due to B19V infection occur in the 2nd trimester.
> Fetal death usually occurs 4-6 weeks post infection but have been reported up to 12 weeks after symptomatic infection.
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WHAt ArE tHE COnsEquEnCEs OF B19v InFECtIOn FOr tHE mOtHEr?
• Most pregnant women are asymptomatic.
• some may experience exanthem and arthralgia.
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Diagnosis
WHAt Is tHE ImmunE rEspOnsE FOllOWIng B19v InFECtIOn?
• IgM antibodies are present in 90% of patients approximately 2 weeks after infection.
• IgM levels can peak around 30 days post-infection and may last up to 4 months.
• Igg antibodies start to appear after 3-4 weeks and most probably persist for life. 6 HOW CAn A WOmAn At rIsk OF InFECtIOn BE IDEntIFIED?
• screening patients for their B19V antibody status will identify a patient at risk of infection.
• a variety of diagnostic assays are available to detect the presence of IgM and Igg antibodies in serum. > appropriate patient management is dependent on accurate B19V diagnosis.
> screening patients for B19V antibody status will determine the need for further follow-up.
> an Igg-positive, IgM-negative patient should be reassured that B19V infection is not a cause for concern during their pregnancy.
WHAt ArE tHE trEAtmEnt OptIOns FOr B19v
InFECtIOn DurIng prEgnAnCy?
> For moderate to severe hydrops, fetal blood sampling may be appropriate.
> If the reticulocyte count is high, marrow aplasia is already in the resolution stage and hydrops should resolve without therapy.
> If hydrops develops, an intrauterine blood transfusion via cordocentesis should be considered.
> The severely anemic fetus with a low reticulocyte count may benefit from immediate transfusion.
> high-titre intravenous immunoglobulin has been reported to be an effective therapy.
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> ultra-sound exams should be performed every 1-2 weeks for up to 6-8 weeks.
> The algorithm of care shown on page 9 outlines treatment options based on serology assay results.
HOW WIll EDuCAtIOn rEgArDIng B19v
InFECtIOn BE OF HElp tO tHE prEgnAnt WOmAn?
> It will allow them to avoid situations that involve possible risk of exposure.
> Patient monitoring of fetal movement would also serve as an important aid to fetal surveillance in women beyond gestation week 28. 
